FDA Approves Botox to Curb Underarm Sweating
Posted on: Tuesday, 20 July 2004, 06:00 CDT
WASHINGTON (AP) -- It's now official: Wrinkle-smoothing Botox can be injected in the armpits to curb excessive sweating.
On Tuesday, the Food and Drug Administration approved the long-expected new use of Botox, the latest in a range of conditions to be treated by this weakened form of the food-poisoning toxin that causes botulism.
People with a condition called "primary axillary hyperhidrosis" produce four or five times the amount of underarm sweat as is normal. There are various treatments, including powerful antiperspirants, drugs to prevent sweat gland stimulation, even surgery on those glands.
Botox apparently temporarily paralyzes a nerve that stimulates sweat glands. In one study, 91 percent of patients who received Botox underarm injections saw their sweating cut in half in a month, compared with 36 percent of patients given salt-water injections.
Patients can get additional injections every few months. FDA cited one study that found the average duration of response was just under six months.
Before receiving Botox, patients should be checked for other causes of the sweating problem, such as an overactive thyroid, to avoid Botox treatment masking a potentially serious disease, FDA cautioned.
Side effects include injection site pain and bleeding, sweating in other parts of the body, flu-like symptoms, headache, fever, itching and anxiety, FDA said.
Dermatologists have long offered Botox to hyperhidrosis sufferers, but FDA approval means maker Allergan Inc. (AGN) now can advertise the use. Allergan says price varies geographically but the average cost is $750 for both arms.
-----
On the Net:
U.S. Food and Drug Administration
More science, space, and technology from RedNova
Copyright © 2004 The Associated Press. All rights reserved. The information contained in the AP News report may not be published, broadcast, rewritten or redistributed without the prior written authority of The Associated Press.
Related Articles
- Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
- Medicis Announces FDA Approval of PMA Supplement for RESTYLANE; Study Demonstrates RESTYLANE Effect Persisted Up to 18 Months in Duration in 97 Percent of Patients With One Repeat Injection
- Statement From Mark Walton, ViaGen President on FDA Final Risk Assessment on Food From Cloned Animals
- FDA Approves Viruses for Treating Food
- U.S. FDA Approves Dacogen(TM) (Decitabine) For Injection
- Botox Helps Stroke Patients
- Amylin and Lilly Announce FDA Approval of BYETTA(TM) (Exenatide) Injection
- FDA OKs Botox to Curb Underarm Sweating
- Study Claims Botox Can Help Excessive Sweating
 |
 |
User Comments (0)
RSS Feeds